RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT

Noor Ul Ain Rehman

Fri, Jul 11, 2025, 10:27 AM 2 min read

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, Inc. (NASDAQ:DYN) with a price target of $25.00.

A lab technician working with chemicals and equipment to create a novel therapeutic drug.

In other news, Dyne Therapeutics, Inc. (NASDAQ:DYN) announced on June 30 that it entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital. The company expects the transaction to bolster its balance sheet as it continues with DYNE-101 and DYNE-251 through critical clinical and regulatory milestones, for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), respectively.

John Cox, president and chief executive officer of Dyne, stated that the company is well-positioned to execute its plans to deliver functional improvement to the neuromuscular community, supported by “$100 million funded upfront and access to additional capital aligned with clinical, regulatory, and commercial progress.” Dyne Therapeutics, Inc. (NASDAQ:DYN) is also nearing a potential US launch in DMD in 2027.

Dyne Therapeutics, Inc. (NASDAQ:DYN) develops innovative life-transforming therapies for genetically driven muscle diseases. The company has a brand portfolio for muscle diseases, including facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, and Duchenne muscular dystrophy.

While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.